Trial · NCT03305809
Outcomes20
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 20
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in the Continuity of Attention (CoA) Composite Score of the Cognitive Drug Research Computerized Cognition Battery (CDR-CCB) | Baseline, Week 12 | All randomized participants who received at least 1 dose of study drug, who had the baseline efficacy assessment and had at least 1 postdose efficacy assessment. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline on the Alzheimer's Disease Cooperative Study-Clinician Global Impression of Change (ADCS-CGIC) Score | Baseline, Week 12 | All randomized participants who received at least one dose of study drug with baseline and post-baseline CGIC data. | Score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline on the CDR-CCB Power of Attention (PoA) Composite Score | Baseline, Week 12 | All randomized participants who received at least one dose of study drug with baseline and post-baseline CDR-CCB PoA data. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13) | Baseline, Week 12 | All randomized participants who received at least one dose of study drug with baseline and post-baseline ADAS-Cog13 data. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Screening in the Montreal Cognitive Assessment (MoCA) Score | Screening (Baseline), Week 12 | All randomized participants who received at least one dose of study drug with baseline and post-baseline MoCA data. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in the Neuropsychiatric Inventory (NPI) Total Score and Individual Item Scores | Baseline, Week 12 | All randomized participants who received at least one dose of study drug with baseline and post-baseline NPI score data. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in the Epworth Sleepiness Scale (ESS) Score | Baseline, Week 12 | All randomized participants who received at least one dose of study drug with baseline and post-baseline ESS data. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in the Movement Disorder Society's Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Total Score (Sum of Parts I-III) | Baseline, Week 12 | All randomized participants who received at least one dose of study drug with baseline and post-baseline MDS-UPDRS data. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in the Penn Parkinson's Daily Activities Questionnaire-15 (PDAQ-15) Total Score | Baseline, Week 12 | All randomized participants who received at least one dose of study drug with baseline and post-baseline PDAQ-15 data. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test Score | Baseline, Week 12 | All randomized participants who received at least one dose of study drug with baseline and post-baseline D-KEFS data. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change in MDS-UPDRS Parts II (Motor Experiences of Daily Living) and III (Motor Exam) From Baseline to Week 12 | Baseline, Week 12 | All randomized participants who received at least one dose of study drug with baseline and post-baseline MDS-UPDRS data. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Number of Participants Who Met the Potentially Clinically Significant Vital Signs Criteria at 3 Consecutive Time Points at Visit 3 | Visit 3 (Day 1 stopping rules) | All randomized participants who received at least one dose of study drug. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Change From Baseline in Clinic Blood Pressure (BP) to 8 Hours Post Dose | Baseline, 8 Hours Post Dose | All randomized participants who received at least one dose of study drug with baseline and post-baseline BP data. | millimeter of mercury (mmHg) | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Pulse Rate to 8 Hours Post Dose | Baseline, 8 Hours Post Dose | All randomized participants who received at least one dose of study drug with baseline and post-baseline pulse rate data. | beats/min | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline In-clinic BP to Week 12 | Baseline, Week 12 | All randomized participants who received at least one dose of study drug with baseline and post-baseline BP data. | millimeters of mercury (mmHg) | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Pulse Rate to Week 12 | Baseline, Week 12 | All randomized participants who received at least one dose of study drug with baseline and post-baseline pulse rate data. | beats/min | LEAST_SQUARES_MEAN |
| SECONDARY | Change in Home Blood Pressure Measurement (HBPM), for SBP, DBP From Baseline to Week 12 | Baseline, Week 12 | All randomized participants who received at least one dose of study drug with baseline and post-baseline BP data. | mmHg | LEAST_SQUARES_MEAN |
| SECONDARY | Change in HBPM for Pulse Rate From Baseline to Week 12 | Baseline, Week 12 | All randomized participants who received at least one dose of study drug with baseline and post-baseline pulse rate data. | beats/min | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in the Physician Withdrawal Checklist (PWC)-20 Total Score From Week 12 to In-Clinic Follow-up Visit | Week 12, Follow-up (2 Weeks after Week 12) | All randomized participants who received at least one dose of study drug with baseline and post-baseline PWC-20 data. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Pharmacokinetics (PK): Steady-State Trough Plasma Concentrations of LY3154207 | Day 1: 1-3 hours post-dose; Day 7, Day 14 and Day 42: post-dose; Day 84: pre-dose | All randomized participants who received at least one dose of study drug and had evaluable PK data. | nanogram per milliliter (ng/mL) | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03305809/outcomes